Current progress in the development of a prophylactic vaccine for HIV-1

References

• UNAIDS2008 Report on the Global AIDS Epidemic2010 Available from: http://www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/2008/2008_Global_report.aspAccessed 2010 Oct 3
   Google Scholar
• DugganJMLocherAFinkBOkontaCChakrabortyJAdherence to antiretroviral therapy: a survey of factors associated with medication usageAIDS Care20092191141114720024773
   PubMed Web of Science ®Google Scholar
• ThiebautRDaucourtVMerciePLipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Groupe d’Epidemiologie Clinique du Syndrome d’Immunodeficience Acquise en AquitaineClin Infect Dis20003161482148711096016
   PubMed Web of Science ®Google Scholar
• CarrAMillerJLawMCooperDAA syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndromeAIDS2000143F253210716495
   PubMed Web of Science ®Google Scholar
• MondyKYarasheskiKPowderlyWGLongitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individualsClin Infect Dis200336448249012567307
   PubMed Web of Science ®Google Scholar
• NoeAPlumJVerhofstedeCThe latent HIV-1 reservoir in patients undergoing HAART: an archive of pre-HAART drug resistanceJ Antimicrob Chemother200555441041215728140
   PubMed Web of Science ®Google Scholar
• ShacklettBLMucosal immunity to HIV: a review of recent literatureCurr Opin HIV AIDS20083554154719373019
   PubMed Web of Science ®Google Scholar
• BurtonDRDesrosiersRCDomsRWHIV vaccine design and the neutralizing antibody problemNat Immunol20045323323614985706
   PubMed Web of Science ®Google Scholar
• McMichaelAJHIV vaccinesAnnu Rev Immunol20062422725516551249
   PubMed Web of Science ®Google Scholar
• EminiEAKoffWCAIDS/HIV. Developing an AIDS vaccine: need, uncertainty, hopeScience200430456791913191415218131
   PubMed Web of Science ®Google Scholar
• ThornerARBarouchDHHIV-1 vaccine development: progress and prospectsCurr Infect Dis Rep200791717517254507
   PubMedGoogle Scholar
• RobinsonHLAmaraRRT cell vaccines for microbial infectionsNat Med200511Suppl 4S253215812486
   PubMed Web of Science ®Google Scholar
• SekalyRPThe failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?J Exp Med2008205171218195078
   PubMed Web of Science ®Google Scholar
• AlmondNKentKCranageMRudEClarkeBStottEJProtection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cellsLancet19953458961134213447752758
   PubMed Web of Science ®Google Scholar
• Stahl-HennigCDittmerUNissleinTRapid development of vaccine protection in macaques by live-attenuated simian immuno-deficiency virusJ Gen Virol199677Pt 12296929819000087
   PubMed Web of Science ®Google Scholar
• LearmontJTindallBEvansLLong-term symptomless HIV-1 infection in recipients of blood products from a single donorLancet199234088248638671357294
   PubMed Web of Science ®Google Scholar
• BerkhoutBVerhoefKvan WamelJLBackNKGenetic instability of live, attenuated human immunodeficiency virus type 1 vaccine strainsJ Virol1999732113811459882315
   PubMed Web of Science ®Google Scholar
• LearmontJCookLDunckleyHSullivanJSUpdate on long-term symptomless HIV type 1 infection in recipients of blood products from a single donorAIDS Res Hum Retroviruses199511117734182
   PubMed Web of Science ®Google Scholar
• DuerrAWasserheitJNCoreyLHIV vaccines: new frontiers in vaccine developmentClin Infect Dis200643450051116838241
   PubMed Web of Science ®Google Scholar
• FlynnNMForthalDNHarroCDJudsonFNMayerKHParaMFPlacebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infectionJ Infect Dis2005191565466515688278
   PubMed Web of Science ®Google Scholar
• GilbertPBPetersonMLFollmannDCorrelation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trialJ Infect Dis2005191566667715688279
   PubMed Web of Science ®Google Scholar
• GrahamBSMascolaJRLessons from failure – preparing for future HIV-1 vaccine efficacy trialsJ Infect Dis2005191564764915688276
   PubMed Web of Science ®Google Scholar
• PitisuttithumPGilbertPGurwithMRandomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, ThailandJ Infect Dis2006194121661167117109337
   PubMed Web of Science ®Google Scholar
• HemelaarJGouwsEGhysPDOsmanovSGlobal and regional distribution of HIV-1 genetic subtypes and recombinants in 2004AIDS20062016W132317053344
   PubMed Web of Science ®Google Scholar
• PlantierJCLeozMDickersonJEA new human immunodeficiency virus derived from gorillasNat Med200915887187219648927
   PubMed Web of Science ®Google Scholar
• RenjifoBGilbertPChaplinBPreferential in-utero transmission of HIV-1 subtype C as compared to HIV-1 subtype A or DAIDS200418121629163615280773
   PubMed Web of Science ®Google Scholar
• BhoopatLRithapornTSKhunamornpongSBhoopatTTaylorCRThornerPSCell reservoirs in lymph nodes infected with HIV-1 subtype E differ from subtype B: identification by combined in situ polymerase chain reaction and immunohistochemistryMod Pathol200619225526316341147
   PubMed Web of Science ®Google Scholar
• VasanARenjifoBHertzmarkEDifferent rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtypeClin Infect Dis200642684385216477563
   PubMed Web of Science ®Google Scholar
• KaleebuPNankyaILYirrellDLRelation between chemokine receptor use, disease stage, and HIV-1 subtypes A and D: results from a rural Ugandan cohortJ Acquir Immune Defic Syndr2007451283317310935
   PubMed Web of Science ®Google Scholar
• CohenJHIV. Escape artist par excellenceScience200329956121505150812624245
   PubMed Web of Science ®Google Scholar
• MooreJPParrenPWBurtonDRGenetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine developmentJ Virol200175135721572911390574
   PubMed Web of Science ®Google Scholar
• McBurneySPRossTMViral sequence diversity: challenges for AIDS vaccine designsExpert Rev Vaccines2008791405141718980542
   PubMed Web of Science ®Google Scholar
• SeamanMSLeblancDFGrandpreLEStandardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogensVirology2007367117518617599382
   PubMed Web of Science ®Google Scholar
• KibuukaHKimutaiRMabokoLA phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172)J Infect Dis2010201460060720078213
   PubMed Web of Science ®Google Scholar
• SantraSLiaoHXZhangRMosaic vaccines elicit CD8(+) T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeysNat Med201016332432820173754
   PubMed Web of Science ®Google Scholar
• CoreyLMcElrathMJHIV vaccines: mosaic approach to virus diversityNat Med201016326827020208511
   PubMed Web of Science ®Google Scholar
• BarouchDHO’BrienKLSimmonsNLMosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeysNat Med201016331932320173752
   PubMed Web of Science ®Google Scholar
• ParrenPWMarxPAHessellAJAntibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitroJ Virol200175178340834711483779
   PubMed Web of Science ®Google Scholar
• BabaTWLiskaVHofmann-LehmannRHuman neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infectionNat Med20006220020610655110
   PubMed Web of Science ®Google Scholar
• MascolaJRStieglerGVanCottTCProtection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodiesNat Med20006220721010655111
   PubMed Web of Science ®Google Scholar
• KorberBGaschenBYusimKThakallapallyRKesmirCDetoursVEvolutionary and immunological implications of contemporary HIV-1 variationBr Med Bull200158194211714622
   PubMed Web of Science ®Google Scholar
• WyattRKwongPDDesjardinsEThe antigenic structure of the HIV gp120 envelope glycoproteinNature199839366867057119641684
   PubMed Web of Science ®Google Scholar
• KwongPDWyattRRobinsonJSweetRWSodroskiJHendricksonWAStructure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibodyNature199839366866486599641677
   PubMed Web of Science ®Google Scholar
• WeiXDeckerJMWangSAntibody neutralization and escape by HIV-1Nature2003422692930731212646921
   PubMed Web of Science ®Google Scholar
• FenouilletEBarboucheRJonesIMCell entry by enveloped viruses: redox considerations for HIV and SARS-coronavirusAntioxid Redox Signal2007981009103417567241
   PubMed Web of Science ®Google Scholar
• DeVicoAFoutsTLewisGKAntibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogensProc Natl Acad Sci U S A200710444174771748217956985
   PubMed Web of Science ®Google Scholar
• WalkerLMPhogatSKChan-HuiPYBroad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine targetScience2009326595028528919729618
   PubMed Web of Science ®Google Scholar
• BurtonDRPyatiJKoduriREfficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibodyScience19942665187102410277973652
   PubMed Web of Science ®Google Scholar
• MusterTSteindlFPurtscherMA conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1J Virol19936711664266477692082
   PubMed Web of Science ®Google Scholar
• StieglerGKunertRPurtscherMA potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1AIDS Res Hum Retroviruses200117181757176511788027
   PubMed Web of Science ®Google Scholar
• TrkolaAPomalesABYuanHCross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgGJ Virol19956911660966177474069
   PubMed Web of Science ®Google Scholar
• LagenaurLAVillarroelVABundocVDeyBBergerEAsCD4-17b bifunctional protein: extremely broad and potent neutralization of HIV-1 Env pseudotyped viruses from genetically diverse primary isolatesRetrovirology201071120158904
   PubMed Web of Science ®Google Scholar
• CortiDLangedijkJPHinzAAnalysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individualsPLoS One201051e880520098712
   PubMed Web of Science ®Google Scholar
• EasterbrookPJSchragerLKLong-term nonprogression in HIV infection: methodological issues and scientific prioritiesReport of an International European Community-National Institutes of Health Workshop, The Royal SocietyLondon, England1995 Nov 27–29Scientific Coordinating CommitteeAIDS Res Hum Retroviruses19981414121112289764904
   PubMedGoogle Scholar
• ParoliMPropatoAAccapezzatoDFrancavillaVSchiaffellaEBarnabaVThe immunology of HIV-infected long-term nonprogressors– a current viewImmunol Lett20017912127129
   Web of Science ®Google Scholar
• JohnsonBKStoneGALong-term observations of human immunodeficiency virus-infected chimpanzeesAIDS Res Hum Retroviruses1993943753788352831
   PubMed Web of Science ®Google Scholar
• GardnerMBSimian and feline immunodeficiency viruses: animal lentivirus models for evaluation of AIDS vaccines and antiviral agentsAntiviral Res19911542672861659310
   PubMed Web of Science ®Google Scholar
• PodellMMarchPABuckWRMathesLEThe feline model of neuroAIDS: understanding the progression towards AIDS dementiaJ Psychopharmacol200014320521311106298
   PubMed Web of Science ®Google Scholar
• YamamotoJKSanouMPAbbottJRColemanJKFeline immunodeficiency virus model for designing HIV/AIDS vaccinesCurr HIV Res201081142520210778
   PubMed Web of Science ®Google Scholar
• MosierDEGuliziaRJBairdSMWilsonDBSpectorDHSpectorSAHuman immunodeficiency virus infection of human-PBL-SCID miceScience199125149957917941990441
   PubMed Web of Science ®Google Scholar
• McCuneJMNamikawaRShihCCRabinLKaneshimaHSuppression of HIV infection in AZT-treated SCID-hu miceScience199024749425645662300816
   PubMed Web of Science ®Google Scholar
• BaenzigerSTussiwandRSchlaepferEDisseminated and sustained HIV infection in CD34+ cord blood cell-transplanted Rag2−/−gamma c−/− miceProc Natl Acad Sci U S A200610343159511595617038503
   PubMed Web of Science ®Google Scholar
• GardnerMBLuciwPAAnimal models of AIDSFASEB J1989314259326062556312
   PubMed Web of Science ®Google Scholar
• LiJLordCIHaseltineWLetvinNLSodroskiJInfection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteinsJ Acquir Immune Defic Syndr1992576396461613662
   PubMed Web of Science ®Google Scholar
• ReimannKALiJTVeazeyRA chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeysJ Virol19967010692269288794335
   PubMed Web of Science ®Google Scholar
• NishimuraYIgarashiTDonauOKHighly pathogenic SHIVs and SIVs target different CD4+ T cell subsets in rhesus monkeys, explaining their divergent clinical coursesProc Natl Acad Sci U S A200410133123241232915297611
   PubMed Web of Science ®Google Scholar
• BuchbinderSPMehrotraDVDuerrAEfficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trialLancet200837296531881189319012954
   PubMed Web of Science ®Google Scholar
• ShiverJWFuTMChenLReplication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunityNature2002415686933133511797011
   PubMed Web of Science ®Google Scholar
• KestlerHWIIIRinglerDJMoriKImportance of the nef gene for maintenance of high virus loads and for development of AIDSCell19916546516622032289
   PubMed Web of Science ®Google Scholar
• DanielMDKirchhoffFCzajakSCSehgalPKDesrosiersRCProtective effects of a live attenuated SIV vaccine with a deletion in the nef geneScience19922585090193819411470917
   PubMed Web of Science ®Google Scholar
• RudEWCranageMYonJMolecular and biological characterization of simian immunodeficiency virus macaque strain 32H proviral clones containing nef size variantsJ Gen Virol199475Pt 35295438126450
   PubMed Web of Science ®Google Scholar
• CranageMPWhatmoreAMSharpeSAMacaques infected with live attenuated SIVmac are protected against superinfection via the rectal mucosaVirology199722911431549123856
   PubMed Web of Science ®Google Scholar
• MarthasMLSutjiptoSHigginsJImmunization with a live, attenuated simian immunodeficiency virus (SIV) prevents early disease but not infection in rhesus macaques challenged with pathogenic SIVJ Virol1990648369437002164591
   PubMed Web of Science ®Google Scholar
• ShacklettBLShawKEAdamsonLALive, attenuated simian immunodeficiency virus SIVmac-M4, with point mutations in the Env transmembrane protein intracytoplasmic domain, provides partial protection from mucosal challenge with pathogenic SIVmac251J Virol20027622113651137812388697
   PubMed Web of Science ®Google Scholar
• Protection of macaques against simian immunodeficiency virus infection with inactivated vaccines: comparison of adjuvants, doses and challenge viruses. The European Concerted Action on ‘Macaque Models for AIDS Research’Vaccine19951332953007631516
   PubMed Web of Science ®Google Scholar
• PutkonenPNilssonCHildKWhole inactivated SIV vaccine grown on human cells fails to protect against homologous SIV grown on simian cellsJ Med Primatol19932223100103
   Web of Science ®Google Scholar
• Stahl-HennigCVossGDittmerUProtection of monkeys by a split vaccine against SIVmac depends upon biological properties of the challenge virusAIDS1993767877958363756
   PubMed Web of Science ®Google Scholar
• KusuharaHHohdatsuTOkumuraMDual-subtype vaccine (Fel-O-Vax FIV) protects cats against contact challenge with heterologous subtype B FIV infected catsVet Microbiol200510834155165
   Web of Science ®Google Scholar
• PuRColemanJOmoriMDual-subtype FIV vaccine protects cats against in vivo swarms of both homologous and heterologous subtype FIV isolatesAIDS200115101225123711426067
   PubMed Web of Science ®Google Scholar
• HohdatsuTOkadaSMotokawaKAizawaCYamamotoJKKoyamaHEffect of dual-subtype vaccine against feline immunodeficiency virus infectionVet Microbiol19975824155165
   Web of Science ®Google Scholar
• PuRColemanJCoismanJDual-subtype FIV vaccine (Fel-O-Vax FIV) protection against a heterologous subtype B FIV isolateJ Feline Med Surg200571657015686976
   PubMed Web of Science ®Google Scholar
• BirxDLLoomis-PriceLDAronsonNEfficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 hase II Vaccine InvestigatorsJ Infect Dis2000181388188910720508
   PubMed Web of Science ®Google Scholar
• EronJJJrAshbyMAGiordanoMFRandomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infectionLancet19963489041154715518950881
   PubMed Web of Science ®Google Scholar
• PontesilliOGuerraECAmmassariAPhase II controlled trial of post-exposure immunization with recombinant gp160 versus antiretroviral therapy in asymptomatic HIV-1-infected adults. VaxSyn Protocol TeamAIDS19981254734809543445
   PubMed Web of Science ®Google Scholar
• Ratto-KimSSitzKVGarnerRPRepeated immunization with recombinant gp160 human immunodeficiency virus (HIV) envelope protein in early HIV-1 infection: evaluation of the T cell proliferative responseJ Infect Dis199917923373449878016
   PubMed Web of Science ®Google Scholar
• RedfieldRRBirxDLKetterNA phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral ResearchN Engl J Med199132424167716841674589
   PubMed Web of Science ®Google Scholar
• SchooleyRTSpinoCKuritzkesDTwo double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS Clinical Trials Groups 209 a nd 214J Infect Dis200018251357136411023459
   PubMed Web of Science ®Google Scholar
• ValentineFTKunduSHaslettPAA randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with > or = 400/mm3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137)
   Google Scholar
• WahrenBBrattGPerssonCImproved cell-mediated immune responses in HIV-1-infected asymptomatic individuals after immunization with envelope glycoprotein gp160J Acquir Immune Defic Syndr1994732202297906300
   PubMed Web of Science ®Google Scholar
• WrightPFLambertJSGorseGJImmunization with envelope MN rgp120 vaccine in human immunodeficiency virus-infected pregnant womenJ Infect Dis199918041080108810479134
   PubMed Web of Science ®Google Scholar
• WeberJCheinsong-PopovRCallowDImmunogenicity of the yeast recombinant p17/p24:Ty virus-like particles (p24-VLP) in healthy volunteersVaccine19951398318347483805
   PubMed Web of Science ®Google Scholar
• VeenstraJWilliamsIGColebundersRImmunization with recombinant p17/p24:Ty virus-like particles in human immunodeficiency virus-infected personsJ Infect Dis199617448628668843231
   PubMed Web of Science ®Google Scholar
• KelleherADRoggensackMJaramilloABSafety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. Community HIV Research Network InvestigatorsAIDS19981221751829468366
   PubMed Web of Science ®Google Scholar
• BensonEMClarksonJLawMTherapeutic vaccination with p24-VLP and zidovudine augments HIV-specific cytotoxic T lymphocyte activity in asymptomatic HIV-infected individualsAIDS Res Hum Retroviruses199915210511310029243
   PubMed Web of Science ®Google Scholar
• OkudaKBukawaHHamajimaKInduction of potent humoral and cell-mediated immune responses following direct injection of DNA encoding the HIV type 1 env and rev gene productsAIDS Res Hum Retroviruses19951189339437492440
   PubMed Web of Science ®Google Scholar
• NeumannJStitzJKonigRRetroviral vectors for vaccine development: induction of HIV-1-specific humoral and cellular immune responses in rhesus macaques using a novel MLV(HIV-1) pseudotype vectorJ Biotechnol2006124361562516563543
   PubMed Web of Science ®Google Scholar
• BuffaVNegriDRLeonePA single administration of lentiviral vectors expressing either full-length human immunodeficiency virus 1 (HIV-1)(HXB2) Rev/Env or codon-optimized HIV-1(JR-FL) gp120 generates durable immune responses in miceJ Gen Virol200687Pt 61625163416690927
   PubMed Web of Science ®Google Scholar
• FaulEJAyePPPapaneriABRabies virus-based vaccines elicit neutralizing antibodies, poly-functional CD8+ T cell, and protect rhesus macaques from AIDS-like disease after SIV(mac251) challengeVaccine200928229930819879223
   PubMed Web of Science ®Google Scholar
• McKennaPMKoserMLCarlsonKRHighly attenuated rabies virus-based vaccine vectors expressing simian-human immunodeficiency virus89.6P Env and simian immunodeficiency virusmac239 Gag are safe in rhesus macaques and protect from an AIDS-like diseaseJ Infect Dis2007195798098817330788
   PubMed Web of Science ®Google Scholar
• QuinnanGVJrYuXFLewisMGProtection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cellsJ Virol20057963358336915731230
   PubMed Web of Science ®Google Scholar
• Rerks-NgarmSPitisuttithumPNitayaphanSVaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in ThailandN Engl J Med2009361232209222019843557
   PubMed Web of Science ®Google Scholar
• JohnsonPRSchneppBCZhangJVector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeysNat Med200915890190619448633
   PubMed Web of Science ®Google Scholar
• ChencinerNRandrianarison-JewtoukoffVDelpeyrouxFEnhancement of humoral immunity to SIVenv following simultaneous inoculation of mice by three recombinant adenoviruses encoding SIVenv/poliovirus chimeras, Tat and RevAIDS Res Hum Retroviruses19971398018069171225
   PubMed Web of Science ®Google Scholar
• SantraSSeamanMSXuLReplication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primatesJ Virol200579106516652215858035
   PubMed Web of Science ®Google Scholar
• NatukRJDavisARChandaPKAdenovirus vectored vaccinesDev Biol Stand19948271777958485
   PubMedGoogle Scholar
• BruceCBAkriggASharpeSAHankeTWilkinsonGWCranageMPReplication-deficient recombinant adenoviruses expressing the human immunodeficiency virus Env antigen can induce both humoral and CTL immune responses in miceJ Gen Virol199980Pt 102621262810573155
   PubMed Web of Science ®Google Scholar
• ZhanXMartinLNSlobodKSMulti-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIVVaccine200523464753065320
   Web of Science ®Google Scholar
• LaubeLSBurrascanoMDejesusCECytotoxic T lymphocyte and antibody responses generated in rhesus monkeys immunized with retroviral vector-transduced fibroblasts expressing human immunodeficiency virus type-1 IIIB ENV/REV proteinsHum Gene Ther1994578538627981310
   PubMed Web of Science ®Google Scholar
• BuffaVNegriDRLeonePEvaluation of a self-inactivating lentiviral vector expressing simian immunodeficiency virus gag for induction of specific immune responses in vitro and in vivoViral Immunol200619469070117201664
   PubMed Web of Science ®Google Scholar
• HalseyRJTanzerFLMeyersAChimaeric HIV-1 subtype C Gag molecules with large in-frame C-terminal polypeptide fusions form virus-like particlesVirus Res2008133225926818329748
   PubMed Web of Science ®Google Scholar
• PillaySMeyersAWilliamsonALRybickiEPOptimization of chimeric HIV-1 virus-like particle production in a baculovirus-insect cell expression systemBiotechnol Prog20092541153116019572400
   PubMed Web of Science ®Google Scholar
• DemlLKratochwilGOsterriederNKnuchelRWolfHWagnerRIncreased incorporation of chimeric human immunodeficiency virus type 1 gp120 proteins into Pr55 gag virus-like particles by an Epstein-Barr virus gp220/350-derived transmembrane domainVirology1997235110259300033
   PubMed Web of Science ®Google Scholar
• DemlLSchirmbeckRReimannJWolfHWagnerRRecombinant human immunodeficiency Pr55 gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodiesVirology1997235126399300034
   PubMed Web of Science ®Google Scholar
• KangCYLuoLWainbergMALiYDevelopment of HIV/AIDS vaccine using chimeric gag-env virus-like particlesBiol Chem1999380335336410223338
   PubMed Web of Science ®Google Scholar
• DonnellyJJUlmerJBShiverJWLiuMADNA vaccinesAnnu Rev Immunol1997156176489143702
   PubMed Web of Science ®Google Scholar
• GarzonMRBerraondoPCrettazJInduction of gp120-specific protective immune responses by genetic vaccination with linear polyethylenimine-plasmid complexVaccine200523111384139215661387
   PubMed Web of Science ®Google Scholar
• LiuMADNA vaccines: a reviewJ Intern Med2003253440241012653868
   PubMed Web of Science ®Google Scholar
• RaskaMBelakovaJWudattuNKComparison of protective effect of protein and DNA vaccines hsp90 in murine model of systemic candidiasisFolia Microbiol (Praha)2005501778215954537
   PubMed Web of Science ®Google Scholar
• GiriMUgenKEWeinerDBDNA vaccines against human immunodeficiency virus type 1 in the past decadeClin Microbiol Rev200417237038915084506
   PubMed Web of Science ®Google Scholar
• WolffJAMaloneRWWilliamsPDirect gene transfer into mouse muscle in vivoScience19902474949 Pt 1146514681690918
   PubMed Web of Science ®Google Scholar
• CalarotaSAWeinerDBEnhancement of human immunodeficiency virus type 1-DNA vaccine potency through incorporation of T-helper 1 molecular adjuvantsImmunol Rev2004199849915233728
   PubMed Web of Science ®Google Scholar
• Billaut-MulotOIdziorekTLoyensMCapronABahrGMModulation of cellular and humoral immune responses to a multiepitopic HIV-1 DNA vaccine by interleukin-18 DNA immunization/viral protein boostVaccine200119202228032811
   Web of Science ®Google Scholar
• DaleCJde RoseRWilsonKMEvaluation in macaques of HIV-1 DNA vaccines containing primate CpG motifs and fowlpoxvirus vaccines co-expressing IFNgamma or IL-12Vaccine200423218819715531036
   PubMed Web of Science ®Google Scholar
• BarouchDHSantraSSteenbekeTDAugmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administrationJ Immunol19981614187518829712056
   PubMed Web of Science ®Google Scholar
• HashidaMNishikawaMYamashitaFTakakuraYCell-specific delivery of genes with glycosylated carriersAdv Drug Deliv Rev200152318719611718943
   PubMed Web of Science ®Google Scholar
• ZhangYSchlachetzkiFLiJYBoadoRJPardridgeWMOrgan-specific gene expression in the rhesus monkey eye following intravenous non-viral gene transferMol Vis2003946547214551536
   PubMed Web of Science ®Google Scholar
• ZouSMErbacherPRemyJSBehrJPSystemic linear polyethylenimine (L-PEI)-mediated gene delivery in the mouseJ Gene Med20002212813410809146
   PubMed Web of Science ®Google Scholar
• ZuberGZammut-ItalianoLDautyEBehrJPTargeted gene delivery to cancer cells: directed assembly of nanometric DNA particles coated with folic acidAngew Chem Int Ed Engl200342232666266912813749
   PubMed Web of Science ®Google Scholar
• HarariABartPAStohrWAn HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responsesJ Exp Med20082051637718195071
   PubMed Web of Science ®Google Scholar
• JaokoWKaritaEKayitenkoreKSafety and immunogenicity study of multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in AfricaPLoS One201059e1287320877623
   PubMed Web of Science ®Google Scholar
• CombeEPirmanTStekarJHoulierMLMirandPPDifferential effect of lentil feeding on proteosynthesis rates in the large intestine, liver and muscle of ratsJ Nutr Biochem2004151121714711455
   PubMed Web of Science ®Google Scholar
• RaskaMMoldoveanuZNovakJDelivery of DNA HIV-1 vaccine to the liver induces high and long-lasting humoral immune responsesVaccine200826121541155118304708
   PubMed Web of Science ®Google Scholar
• LetvinNLWalkerBDImmunopathogenesis and immunotherapy in AIDS virus infectionsNat Med20039786186612835706
   PubMed Web of Science ®Google Scholar
• ReitterJNMeansREDesrosiersRCA role for carbohydrates in immune evasion in AIDSNat Med1998466796849623976
   PubMed Web of Science ®Google Scholar
• HellerLJaroszeskiMJCoppolaDPottingerCGilbertRHellerRElectrically mediated plasmid DNA delivery to hepatocellular carcinomas in vivoGene Ther200071082682910845719
   PubMed Web of Science ®Google Scholar
• Vorup-JensenTJensenUBLiuHTail-vein injection of mannan-binding lectin DNA leads to high expression levels of multimeric protein in liverMol Ther20013686787411407900
   PubMed Web of Science ®Google Scholar
• BudkerVGSubbotinVMBudkerTSebestyenMGZhangGWolffJAMechanism of plasmid delivery by hydrodynamic tail vein injection. II. Morphological studiesJ Gene Med20068787488816718734
   PubMed Web of Science ®Google Scholar
• SebestyenMGBudkerVGBudkerTMechanism of plasmid delivery by hydrodynamic tail vein injection. I. Hepatocyte uptake of various moleculesJ Gene Med20068785287316724360
   PubMed Web of Science ®Google Scholar
• BudkerVZhangGDankoIWilliamsPWolffJThe efficient expression of intravascularly delivered DNA in rat muscleGene Ther1998522722769578848
   PubMed Web of Science ®Google Scholar
• LiuFSongYLiuDHydrodynamics-based transfection in animals by systemic administration of plasmid DNAGene Ther1999671258126610455434
   PubMed Web of Science ®Google Scholar
• ZhangGBudkerVWolffJAHigh levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNAHum Gene Ther199910101735173710428218
   PubMed Web of Science ®Google Scholar
• SudaTLiuDHydrodynamic gene delivery: its principles and applicationsMol Ther200715122063206917912237
   PubMed Web of Science ®Google Scholar
• StockertRJThe asialoglycoprotein receptor: relationships between structure, function, and expressionPhysiol Rev19957535916097624395
   PubMed Web of Science ®Google Scholar
• MaierMAYannopoulosCGMohamedNSynthesis of antisense oligonucleotides conjugated to a multivalent carbohydrate cluster for cellular targetingBioconjug Chem2003141182912526688
   PubMed Web of Science ®Google Scholar
• WaddingtonSNMcVeyJHBhellaDAdenovirus serotype 5 hexon mediates liver gene transferCell2008132339740918267072
   PubMed Web of Science ®Google Scholar
• KalyuzhniyOdi PaoloNCSilvestryMAdenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivoProc Natl Acad Sci U S A2008105145483548818391209
   PubMed Web of Science ®Google Scholar
• LiSLockeEBruderJViral vectors for malaria vaccine developmentVaccine200725142567257416914237
   PubMed Web of Science ®Google Scholar
• SmithADGeislerSCChenAAHuman rhinovirus type 14:human immunodeficiency virus type 1 (HIV-1) V3 loop chimeras from a combinatorial library induce potent neutralizing antibody responses against HIV-1J Virol19987216516599420270
   PubMed Web of Science ®Google Scholar
• ArnoldGFVelascoPKHolmesAKBroad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitopeJ Virol200983105087510019279101
   PubMed Web of Science ®Google Scholar
• PattersonSPapagatsiasTBenlahrechAUse of adenovirus in vaccines for HIVHandb Exp Pharmacol200918827529319031031
   PubMedGoogle Scholar
• BangariDSMittalSKDevelopment of nonhuman adenoviruses as vaccine vectorsVaccine200624784986216297508
   PubMed Web of Science ®Google Scholar
• CrottySAndinoRPoliovirus vaccine strains as mucosal vaccine vectors and their potential use to develop an AIDS vaccineAdv Drug Deliv Rev200456683585215063593
   PubMed Web of Science ®Google Scholar
• AmaraRRVillingerFAltmanJDControl of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccineScience20012925514697411393868
   PubMed Web of Science ®Google Scholar
• GherardiMMEstebanMRecombinant poxviruses as mucosal vaccine vectorsJ Gen Virol200586Pt 112925293616227213
   PubMed Web of Science ®Google Scholar
• LangleyWABradleyKCLiZNSmithMESchnellMJSteinhauerDAInduction of neutralizing antibody responses to anthrax protective antigen by using influenza virus vectors: implications for disparate immune system priming pathwaysJ Virol201084168300830720504926
   PubMed Web of Science ®Google Scholar
• SlobodKSLockeyTDHowlettNSubcutaneous administration of a recombinant vaccinia virus vaccine expressing multiple envelopes of HIV-1Eur J Clin Microbiol Infect Dis200423210611014735404
   PubMed Web of Science ®Google Scholar
• DmitrievIKrasnykhVMillerCRAn adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanismJ Virol19987212970697139811704
   PubMed Web of Science ®Google Scholar
• BarnettBGCrewsCJDouglasJTTargeted adenoviral vectorsBiochim Biophys Acta200215751311412020813
   PubMed Web of Science ®Google Scholar
• KayMAGloriosoJCNaldiniLViral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeuticsNat Med200171334011135613
   PubMed Web of Science ®Google Scholar
• TangyFNaimHYLive attenuated measles vaccine as a potential multivalent pediatric vaccination vectorViral Immunol200518231732616035943
   PubMed Web of Science ®Google Scholar
• EsolenLMWardBJMoenchTRGriffinDEInfection of monocytes during measlesJ Infect Dis1993168147528515132
   PubMed Web of Science ®Google Scholar
• HillemanMRVaccinology, immunology, and comparative pathogenesis of measles in the quest for a preventative against AIDSAIDS Res Hum Retroviruses19941013128179962
   PubMed Web of Science ®Google Scholar
• MandlSHixLAndinoRPreexisting immunity to poliovirus does not impair the efficacy of recombinant poliovirus vaccine vectorsJ Virol200175262262711134275
   PubMed Web of Science ®Google Scholar
• ThackerETimaresLMatthewsQLStrategies to overcome host immunity to adenovirus vectors in vaccine developmentExpert Rev Vaccines20098676177719485756
   PubMed Web of Science ®Google Scholar
• SumidaSMTruittDMLemckertAANeutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon proteinJ Immunol2005174117179718515905562
   PubMed Web of Science ®Google Scholar
• WuHDmitrievIKashentsevaESekiTWangMCurielDTConstruction and characterization of adenovirus serotype 5 packaged by serotype 3 hexonJ Virol20027624127751278212438602
   PubMed Web of Science ®Google Scholar
• RobertsDMNandaAHavengaMJHexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunityNature2006441709023924316625206
   PubMed Web of Science ®Google Scholar
• ChirmuleNPropertKMagosinSQianYQianRWilsonJImmune responses to adenovirus and adeno-associated virus in humansGene Ther1999691574158310490767
   PubMed Web of Science ®Google Scholar
• Kass-EislerAFalck-PedersenEElfenbeinDHAlviraMButtrickPMLeinwandLAThe impact of developmental stage, route of administration and the immune system on adenovirus-mediated gene transferGene Ther1994163954027584105
   PubMed Web of Science ®Google Scholar
• Kass-EislerALeinwandLGallJBloomBFalck-PedersenECircumventing the immune response to adenovirus-mediated gene therapyGene Ther1996321541628867863
   PubMed Web of Science ®Google Scholar
• YouilRTonerTJSuQHexon gene switch strategy for the generation of chimeric recombinant adenovirusHum Gene Ther200213231132011812286
   PubMed Web of Science ®Google Scholar
• MastrangeliAHarveyBGYaoJ‘Sero-switch’ adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotypeHum Gene Ther19967179878825871
   PubMed Web of Science ®Google Scholar
• MoffattSHaysJHogenEschHMittalSKCircumvention of vector-specific neutralizing antibody response by alternating use of human and non-human adenoviruses: implications in gene therapyVirology2000272115916710873758
   PubMed Web of Science ®Google Scholar
• LemckertAAGrimbergenJSmitsSGeneration of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicityJ Gen Virol200687Pt 102891289916963747
   PubMed Web of Science ®Google Scholar
• ShayakhmetovDMLieberADependence of adenovirus infectivity on length of the fiber shaft domainJ Virol20007422102741028611044071
   PubMed Web of Science ®Google Scholar
• KiddAHChroboczekJCusackSRuigrokRWAdenovirus type 40 virions contain two distinct fibersVirology1993192173848517033
   PubMed Web of Science ®Google Scholar
• YehHYPieniazekNPieniazekDGelderblomHLuftigRBHuman adenovirus type 41 contains two fibersVirus Res19943321791987975882
   PubMed Web of Science ®Google Scholar
• Pichla-GollonSLDrinkerMZhouXStructure-based identification of a major neutralizing site in an adenovirus hexonJ Virol20078141680168917108028
   PubMed Web of Science ®Google Scholar
• RoySGaoGLuYCharacterization of a family of chimpanzee adenoviruses and development of molecular clones for gene transfer vectorsHum Gene Ther200415551953015144581
   PubMed Web of Science ®Google Scholar
• FarinaSFGaoGPXiangZQReplication-defective vector based on a chimpanzee adenovirusJ Virol20017523116031161311689642
   PubMed Web of Science ®Google Scholar
• KobingerGPFeldmannHZhiYChimpanzee adenovirus vaccine protects against Zaire Ebola virusVirology2006346239440116356525
   PubMed Web of Science ®Google Scholar
• UmanaPGerdesCAStoneDEfficient FLPe recombinase enables scalable production of helper-dependent adenoviral vectors with negligible helper-virus contaminationNat Biotechnol200119658258511385466
   PubMed Web of Science ®Google Scholar
• LowensteinPRThomasCEUmanaPHigh-capacity, helperdependent, ‘gutless’ adenoviral vectors for gene transfer into brainMethods Enzymol200234629231111883074
   PubMed Web of Science ®Google Scholar
• XiongWGoverdhanaSSciasciaSARegulatable gutless adenovirus vectors sustain inducible transgene expression in the brain in the presence of an immune response against adenovirusesJ Virol2006801273716352528
   PubMed Web of Science ®Google Scholar
• XiongWCandolfiMKroegerKMImmunization against the transgene but not the TetON switch reduces expression from gutless adenoviral vectors in the brainMol Ther200816234335118180781
   PubMed Web of Science ®Google Scholar
• WeaverEANehetePNBuchlSSComparison of replication-competent, first generation, and helper-dependent adenoviral vaccinesPLoS One200943e505919333387
   PubMed Web of Science ®Google Scholar
• WeaverEANehetePNNeheteBPProtection against mucosal SHIV challenge by peptide and helper-dependent adenovirus vaccinesViruses20091392093820107521
   PubMed Web of Science ®Google Scholar
• WeaverEABarryMAEffects of shielding adenoviral vectors with polyethylene glycol (PEG) on vector-specific and vaccine-mediated immune responsesHum Gene Ther200819121369138218778197
   PubMed Web of Science ®Google Scholar
• O’RiordanCRSongAPEGylated adenovirus for targeted gene therapyMethods Mol Biol200843413316018470643
   PubMedGoogle Scholar
• EtoYYoshiokaYMukaiYOkadaNNakagawaSDevelopment of PEGylated adenovirus vector with targeting ligandInt J Pharm20083541238
   Web of Science ®Google Scholar
• EtoYGaoJQSekiguchiFNeutralizing antibody evasion ability of adenovirus vector induced by the bioconjugation of methoxypolyethylene glycol succinimidyl propionate (MPEG-SPA)Biol Pharm Bull200427693693815187452
   PubMed Web of Science ®Google Scholar
• EtoYGaoJQSekiguchiFPEGylated adenovirus vectors containing RGD peptides on the tip of PEG show high transduction efficiency and antibody evasion abilityJ Gene Med20057560461215543536
   PubMed Web of Science ®Google Scholar
• MokHPalmerDJNgPBarryMAEvaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responsesMol Ther2005111667915585407
   PubMed Web of Science ®Google Scholar
• CroyleMALeHTLinseKDPEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profileGene Ther200512757958715647765
   PubMed Web of Science ®Google Scholar
• ZabaletaALlopizDArribillagaLVaccination against hepatitis C virus with dendritic cells transduced with an adenovirus encoding NS3 proteinMol Ther200816121021717923840
   PubMed Web of Science ®Google Scholar
• RothJCCurielDTPereboevaLCell vehicle targeting strategiesGene Ther2008151071672918369326
   PubMed Web of Science ®Google Scholar
• BangariDSMittalSKCurrent strategies and future directions for eluding adenoviral vector immunityCurr Gene Ther20066221522616611043
   PubMed Web of Science ®Google Scholar
• BrownBDShiCXRawleFEFactors influencing therapeutic efficacy and the host immune response to helper-dependent adenoviral gene therapy in hemophilia A miceJ Thromb Haemost20042111111814717974
   PubMed Web of Science ®Google Scholar
• de GeestBSnoeysJvan LinthoutSLievensJCollenDElimination of innate immune responses and liver inflammation by PEGylation of adenoviral vectors and methylprednisoloneHum Gene Ther200516121439145116390275
   PubMed Web of Science ®Google Scholar
• MorralNO’NealWRiceKAdministration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboonsProc Natl Acad Sci U S A19999622128161282110536005
   PubMed Web of Science ®Google Scholar
• HutnickNACarnathanDGDubeySABaseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4+ T cellsNat Med200915887687819620962
   PubMed Web of Science ®Google Scholar
• KaufmanDRBarouchDHTranslational mini-review series on vaccines for HIV: T lymphocyte trafficking and vaccine-elicited mucosal immunityClin Exp Immunol2009157216517319604255
   PubMed Web of Science ®Google Scholar
• KaufmanDRBivas-BenitaMSimmonsNLMillerDBarouchDHRoute of adenovirus-based HIV-1 vaccine delivery impacts the phenotype and trafficking of vaccine-elicited CD8+ T lymphocytesJ Virol201084125986599620357087
   PubMed Web of Science ®Google Scholar
• ChengCGallJGNasonMDifferential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunizationJ Virol201084163063819846512
   PubMed Web of Science ®Google Scholar
• OgraPLKarzonDTDistribution of poliovirus antibody in serum, nasopharynx and alimentary tract following segmental immunization of lower alimentary tract with poliovaccineJ Immunol19691026142314304977607
   PubMed Web of Science ®Google Scholar
• OgraPLOgraSSal-NakeebSCoppolaPRLocal antibody response to experimental poliovirus infection in the central nervous system of rhesus monkeysInfect Immun1973869319374361727
   PubMed Web of Science ®Google Scholar
• AhlersJDBelyakovIMStrategies for optimizing targeting and delivery of mucosal HIV vaccinesEur J Immunol200939102657266919609978
   PubMed Web of Science ®Google Scholar
• MehandruSPolesMATenner-RaczKPrimary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tractJ Exp Med2004200676177015365095
   PubMed Web of Science ®Google Scholar
• BrenchleyJMSchackerTWRuffLECD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tractJ Exp Med2004200674975915365096
   PubMed Web of Science ®Google Scholar
• BelyakovIMHelZKelsallBMucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaquesNat Med20017121320132611726972
   PubMed Web of Science ®Google Scholar
• BelyakovIMKuznetsovVAKelsallBImpact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosaBlood200610783258326416373659
   PubMed Web of Science ®Google Scholar
• BelyakovIMIsakovDZhuQDzutsevABerzofskyJAA novel functional CTL avidity/activity compartmentalization to the site of mucosal immunization contributes to protection of macaques against simian/human immunodeficiency viral depletion of mucosal CD4+ T cellsJ Immunol2007178117211722117513770
   PubMed Web of Science ®Google Scholar
• StaatsHFMontgomerySPPalkerTJIntranasal immunization is superior to vaginal, gastric, or rectal immuni - zation for the induction of systemic and mucosal anti-HIV antibody responsesAIDS Res Hum Retroviruses199713119459529223410
   PubMed Web of Science ®Google Scholar
• KozlowskiPACu-UvinSNeutraMRFlaniganTPComparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of womenInfect Immun1997654138713949119478
   PubMed Web of Science ®Google Scholar
• GorelickRJBenvenisteREGagliardiTDNucleocapsid protein zinc-finger mutants of simian immunodeficiency virus strain mne produce virions that are replication defective in vitro and in vivoVirology199925322592709918884
   PubMed Web of Science ®Google Scholar
• SauterMMPelchen-MatthewsABronRAn internalization signal in the simian immunodeficiency virus transmembrane protein cytoplasmic domain modulates expression of envelope glycoproteins on the cell surfaceJ Cell Biol199613257958118603913
   PubMed Web of Science ®Google Scholar
• HessellAJRakaszEGTehraniDMBroadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-LJ Virol20108431302131319906907
   PubMed Web of Science ®Google Scholar
• NatukRJLubeckMDChandaPKImmunogenicity of recombinant human adenovirus-human immunodeficiency virus vaccines in chimpanzeesAIDS Res Hum Retroviruses1993953954048318268
   PubMed Web of Science ®Google Scholar
• LubeckMDNatukRMyagkikhMLong-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunizationNat Med1997366516589176492
   PubMed Web of Science ®Google Scholar
• PattersonLJMalkevitchNVenzonDProtection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boostingJ Virol20047852212222114963117
   PubMed Web of Science ®Google Scholar
• MalkevitchNRohneDPinczewskiJEvaluation of combination DNA/replication-competent Ad-SIV recombinant immunization regimens in rhesus macaquesAIDS Res Hum Retroviruses200420223524415018712
   PubMed Web of Science ®Google Scholar
• LemialeFHaddadaHNabelGJBroughDEKingCRGallJGNovel adenovirus vaccine vectors based on the enteric-tropic serotype 41Vaccine200725112074208417250935
   PubMed Web of Science ®Google Scholar
• ChristensenMLHuman viral gastroenteritisClin Microbiol Rev19892151892644024
   PubMed Web of Science ®Google Scholar
• FavierALBurmeisterWPChroboczekJUnique physicochemical properties of human enteric Ad41 responsible for its survival and replication in the gastrointestinal tractVirology200432219310415063120
   PubMed Web of Science ®Google Scholar
• PieniazekNJSlemendaSBPieniazekDVelardeJJrLuftigRBHuman enteric adenovirus type 41 (Tak) contains a second fiber protein geneNucleic Acids Res19901871901
   Web of Science ®Google Scholar
• McConnellMJHannaPCImperialeMJAdenovirus-based prime-boost immunization for rapid vaccination against anthraxMol Ther200715120321017164792
   PubMed Web of Science ®Google Scholar
• SullivanNJSanchezARollinPEYangZYNabelGJDevelopment of a preventive vaccine for Ebola virus infection in primatesNature2000408681260560911117750
   PubMed Web of Science ®Google Scholar
• LiuRYWuLZHuangBJAdenoviral expression of a truncated S1 subunit of SARS-CoV spike protein results in specific humoral immune responses against SARS-CoV in ratsVirus Res200511212243116022896
   PubMed Web of Science ®Google Scholar
• Gomez-RomanVRRobert-GuroffMAdenoviruses as vectors for HIV vaccinesAIDS Rev20035317818514598567
   PubMedGoogle Scholar
• McConnellMJDanthinneXImperialeMJCharacterization of a permissive epitope insertion site in adenovirus hexonJ Virol200680115361537016699016
   PubMed Web of Science ®Google Scholar
• SchiefWRBanYEStamatatosLChallenges for structure-based HIV vaccine designCurr Opin HIV AIDS20094543144020048708
   PubMed Web of Science ®Google Scholar
• LinGNaraPLDesigning immunogens to elicit broadly neutralizing antibodies to the HIV-1 envelope glycoproteinCurr HIV Res20075651454118045109
   PubMed Web of Science ®Google Scholar
• WalkerLMBurtonDRRational antibody-based HIV-1 vaccine design: current approaches and future directionsCurr Opin Immunol201022335836620299194
   PubMed Web of Science ®Google Scholar
• LiuJBartesaghiABorgniaMJSapiroGSubramaniamSMolecular architecture of native HIV-1 gp120 trimersNature2008455720910911318668044
   PubMed Web of Science ®Google Scholar
• ZhouTXuLDeyBStructural definition of a conserved neutralization epitope on HIV-1 gp120Nature2007445712973273717301785
   PubMed Web of Science ®Google Scholar
• LifsonJDMartinMAOne step forwards, one step backNature2002415686927227311796990
   PubMed Web of Science ®Google Scholar
• LetvinNLBarouchDHMontefioriDCProspects for vaccine protection against HIV-1 infection and AIDSAnnu Rev Immunol200220739911861598
   PubMed Web of Science ®Google Scholar
• WorgallSBuschARivaraMModification to the capsid of the adenovirus vector that enhances dendritic cell infection and transgene-specific cellular immune responsesJ Virol20047852572258014963160
   PubMed Web of Science ®Google Scholar
• WorgallSKrauseARivaraMProtection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsidJ Clin Invest200511551281128915841217
   PubMed Web of Science ®Google Scholar
• MatthewsQLYangPWuQOptimization of capsid-incorporated antigens for a novel adenovirus vaccine approachJ Virol2008598
   Web of Science ®Google Scholar
• KrauseAJohJHHackettNREpitopes expressed in different adenovirus capsid proteins induce different levels of epitope-specific immunityJ Virol200680115523553016699033
   PubMed Web of Science ®Google Scholar
• CromptonJToogoodCIWallisNHayRTExpression of a foreign epitope on the surface of the adenovirus hexonJ Gen Virol199475Pt 11331397509367
   PubMed Web of Science ®Google Scholar
• WuHHanTBelousovaNIdentification of sites in adenovirus hexon for foreign peptide incorporationJ Virol20057963382339015731232
   PubMed Web of Science ®Google Scholar
• RuxJJKuserPRBurnettRMStructural and phylogenetic analysis of adenovirus hexons by use of high-resolution X-ray crystallographic, molecular modeling, and sequence-based methodsJ Virol200377179553956612915569
   PubMed Web of Science ®Google Scholar
• WorgallSKrauseAQiuJJohJHackettNRCrystalRGProtective immunity to pseudomonas aeruginosa induced with a capsid-modified adenovirus expressing P. aeruginosa OprFJ Virol20078124138011380817942539
   PubMed Web of Science ®Google Scholar
• VigneEMahfouzIDedieuJFBrieAPerricaudetMYehPRGD inclusion in the hexon monomer provides adenovirus type 5-based vectors with a fiber knob-independent pathway for infectionJ Virol19997365156516110233980
   PubMed Web of Science ®Google Scholar
• AbeSOkudaKUraTAdenovirus type 5 with modified hexons induces robust transgene-specific immune responses in mice with pre-existing immunity against adenovirus type 5J Gene Med200911757057919391169
   PubMed Web of Science ®Google Scholar
• OfekGTangMSamborAStructure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitopeJ Virol20047819107241073715367639
   PubMed Web of Science ®Google Scholar
• MatthewsQLSibleyDAWuHGenetic incorporation of a herpes simplex virus type 1 thymidine kinase and firefly luciferase fusion into the adenovirus protein IX for functional display on the virionMol Imaging20065451051917150163
   PubMed Web of Science ®Google Scholar
• TangYLeLPMatthewsQLHanTWuHCurielDTDerivation of a triple mosaic adenovirus based on modification of the minor capsid protein IXVirology2008377239140018570971
   PubMed Web of Science ®Google Scholar
• LiJLeLSibleyDAMathisJMCurielDTGenetic incorporation of HSV-1 thymidine kinase into the adenovirus protein IX for functional display on the virionVirology2005338224725815996701
   PubMed Web of Science ®Google Scholar
• MatthewsQLFatimaATangYHIV antigen incorporation within adenovirus hexon hypervariable 2 for a novel HIV vaccine approachPLoS One201057e1181520676400
   PubMed Web of Science ®Google Scholar
• SmithADResnickDAZhangAGeislerSCArnoldEArnoldGFUse of random systematic mutagenesis to generate viable human rhinovirus 14 chimeras displaying human immunodeficiency virus type 1 V3 loop sequencesJ Virol19946815755798254775
   PubMed Web of Science ®Google Scholar
• BrownTPeerapatanapokinWThe Asian Epidemic Model: a process model for exploring HIV policy and programme alternatives in AsiaSex Transm Infect200480Suppl 1i19i2415249695
   PubMed Web of Science ®Google Scholar
• PhoolcharoenWHIV/AIDS prevention in Thailand: success and challengesScience19982805371187318749669947
   PubMed Web of Science ®Google Scholar
• WenigerBGLimpakarnjanaratKUngchusakKThe epidemiology of HIV infection and AIDS in ThailandAIDS19915Suppl 2S71851845063
   PubMedGoogle Scholar
• NitayaphanSBrownAEPreventive HIV vaccine development in ThailandAIDS199812Suppl BS1551619679641
   PubMedGoogle Scholar
• HanenbergRSRojanapithayakornWKunasolPSokalDCImpact of Thailand’s HIV-control programme as indicated by the decline of sexually transmitted diseasesLancet199434489172432457913163
   PubMed Web of Science ®Google Scholar
• NelsonKECelentanoDDSuprasertSRisk factors for HIV infection among young adult men in northern ThailandJAMA199327089559608345647
   PubMed Web of Science ®Google Scholar
• Rerks-NgarmSBrownAEKhamboonruangCThongcharoenPKunasolPHIV/AIDS preventive vaccine ‘prime-boost’ phase III trial: foundations and initial lessons learned from ThailandAIDS200620111471147916847401
   PubMed Web of Science ®Google Scholar